Stocks

Merck's KRAS Deal May Block Deals with Other Firms

Guavy AI Editorial Team Published September 29, 2026

Instruments

MRK

Bernstein's analyst Courtney Breen said that Merck's licensing agreement for a KRAS inhibitor could eliminate potential deals with other companies, Revolution Medicines and Erasca.

The pharmaceutical giant has licensed SPR2015 from private company SciBrunch for a $400 million upfront payment as part of a total potential value of up to $2.13 billion.

Merck's stock currently trades at $148.36, just 5% below its 52-week high of $156.92.

The Wire

Keep reading for free.

You've read 3 free articles in the last 24 hours. Create a free account for unlimited access, no card required.

Create free account Already have an account? Sign in

No spam. Unsubscribe anytime.

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

Terms Privacy Policy